Evaxion A/S to Announce Q1 2025 Financial Results and Business Update

The latest announcement is out from Evaxion Biotech ( (EVAX) ).

On May 23, 2025, Evaxion A/S announced that it will provide a business update and report its first quarter 2025 financial results on May 27, 2025. The company will host a conference call and webcast to present the update and results, allowing stakeholders to engage and ask questions. This announcement signifies Evaxion’s commitment to transparency and engagement with its investors and stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall stock score reflects significant financial challenges despite strong revenue growth and positive strategic partnerships. While there is optimism from recent clinical successes and strategic partnerships, the persistent net losses, reliance on debt, and negative cash flow are critical concerns impacting the stock’s attractiveness. Technical indicators also suggest some caution.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in AI-Immunology™ powered vaccines. The company leverages artificial intelligence to develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion’s innovative AI platform has led to a clinical-stage oncology pipeline and a preclinical pipeline for infectious diseases, addressing high unmet medical needs.

Average Trading Volume: 74,796

Technical Sentiment Signal: Sell

Current Market Cap: $2.62M

For a thorough assessment of EVAX stock, go to TipRanks’ Stock Analysis page.